Did you know that most new FDA-approved drugs in 2023 were small molecules? These are essential for many pharmaceutical companies and biotechs to find new treatments. At NUVISAN, we provide tailored chemical libraries with millions of compounds and various testing methods to kickstart drug discovery.
Join us for this exciting webinar on May 29th at 5:00 pm CET; to learn more about our unique libraries and how we find potential novel drugs using high-throughput screening (HTS).
Led by experts Dr. Benjamin Bader, Head of Screening and Dr. Stefan Werner, Director of Life Science Chemistry at NUVISAN, this 40-minute seminar will explore:
Screening the right compounds with the right assays by the right scientists is key for every drug discovery project. With comprehensive NUVISAN solutions across the entire drug discovery value chain from target identification to candidate selection, we can provide tailored solutions according to different needs.
Following the presentation, we'll host a Q&A session where you can engage with our speakers and ask any burning questions you may have.
Can't join? Don't worry, register anyway, the slides and recording will be sent to you after the webinar.
